Differences in the immune response to long term Aβ vaccination in C57BL/6 and B6D2F1 mice

被引:18
作者
Seabrook, TJ
Iglesias, M
Bloom, JK
Spooner, ET
Lemere, CA
机构
[1] Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA 02115 USA
关键词
Alzheimer's disease; intranasal A beta immunization; APP transgenic mice;
D O I
10.1016/j.vaccine.2004.03.061
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The cerebral accumulation of beta-amyloid (Abeta) is a pathological hallmark of Alzheimer's disease (AD). Abeta vaccination or anti-Abeta specific antibodies may be a possible therapeutic option for AD. Previously, we demonstrated variation in the humoral response between B6D2F1 and C57BL/6 during short term (14 weeks) Abeta immunization. In the present study, we determined the humoral and cellular immune responses in these same mouse strains to a longer period of Abeta vaccination and further refined the major B cell epitope to Abeta1-7. B6D2F1 mice generated a greater Immoral and Th1 immune response versus C57BL/6 mice. Immunization with 25 mug Abeta produced a greater T cell response in B6D2F1 mice compared to 50 or 100 mug Abeta but resulted in comparable humoral immunity. Thus, Abeta vaccination is affected by the genetic background and amount of Abeta peptide used as immunogen. These data may help explain some differences observed in Abeta immunization studies in mice of various genetic backgrounds and aid in the design of Abeta vaccines. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4075 / 4083
页数:9
相关论文
共 29 条
[1]  
Bacskai BJ, 2002, J NEUROSCI, V22, P7873
[2]   Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease [J].
Bard, F ;
Cannon, C ;
Barbour, R ;
Burke, RL ;
Games, D ;
Grajeda, H ;
Guido, T ;
Hu, K ;
Huang, JP ;
Johnson-Wood, K ;
Khan, K ;
Kholodenko, D ;
Lee, M ;
Lieberburg, I ;
Motter, R ;
Nguyen, M ;
Soriano, F ;
Vasquez, N ;
Weiss, K ;
Welch, B ;
Seubert, P ;
Schenk, D ;
Yednock, T .
NATURE MEDICINE, 2000, 6 (08) :916-919
[3]   Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with β-amyloid [J].
Cribbs, DH ;
Ghochikyan, A ;
Vasilevko, V ;
Tran, M ;
Petrushina, I ;
Sadzikava, N ;
Babikyan, D ;
Kesslak, P ;
Kieber-Emmons, T ;
Cotman, CW ;
Agadjanyan, MG .
INTERNATIONAL IMMUNOLOGY, 2003, 15 (04) :505-514
[4]   Immune responses against Aβ1-42 in HLA class II transgenic mice:: implications for Aβ1-42 immune-mediated therapies [J].
Das, P ;
Chapoval, S ;
Howard, V ;
David, CS ;
Golde, TE .
NEUROBIOLOGY OF AGING, 2003, 24 (07) :969-976
[5]   Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model [J].
Dodart, JC ;
Bales, KR ;
Gannon, KS ;
Greene, SJ ;
DeMattos, RB ;
Mathis, C ;
DeLong, CA ;
Wu, S ;
Wu, X ;
Holtzman, DM ;
Paul, SM .
NATURE NEUROSCIENCE, 2002, 5 (05) :452-457
[6]   Alzheimer disease therapy: Can the amyloid cascade be halted? [J].
Golde, TE .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (01) :11-18
[7]   Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease [J].
Hock, C ;
Konietzko, U ;
Streffer, JR ;
Tracy, J ;
Signorell, A ;
Müller-Tillmanns, B ;
Lemke, U ;
Henke, K ;
Moritz, E ;
Garcia, E ;
Wollmer, MA ;
Umbricht, D ;
de Quervain, DJF ;
Hofmann, M ;
Maddalena, A ;
Papassotiropoulos, A ;
Nitsch, RM .
NEURON, 2003, 38 (04) :547-554
[8]   Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease [J].
Hock, C ;
Konietzko, U ;
Papassotiropoulos, A ;
Wollmer, A ;
Streffer, J ;
von Rotz, RC ;
Davey, G ;
Moritz, E ;
Nitsch, RM .
NATURE MEDICINE, 2002, 8 (11) :1270-1275
[9]  
Kotilinek LA, 2002, J NEUROSCI, V22, P6331
[10]   Intranasal immunotherapy for the treatment of Alzheimer's disease:: Escherichia coli LT and LT(R192G) as mucosal adjuvants [J].
Lemere, CA ;
Spooner, ET ;
Leverone, JF ;
Mori, C ;
Clements, JD .
NEUROBIOLOGY OF AGING, 2002, 23 (06) :991-1000